Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Exenatide

Abstract

In April 2005, exenatide (Byetta; Amylin/Eli Lilly) was approved by the US FDA as an adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes. It is the first in a new class of drugs that mimic the activity of natural glucoregulatory peptides known as incretins.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pathways of diabetic complications.

References

  1. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827 (2001).

    Article  CAS  Google Scholar 

  2. Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655 (1993).

    CAS  PubMed  Google Scholar 

  3. Joy, S. V. et al. Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. 39, 110–118 (2005).

    Article  CAS  Google Scholar 

  4. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021773lbl.pdf> (2005).

  5. Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635 (2004).

    Article  CAS  Google Scholar 

  6. Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091 (2005).

    Article  CAS  Google Scholar 

  7. DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100 (2005).

    Article  CAS  Google Scholar 

  8. U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995).

  9. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).

    Article  CAS  Google Scholar 

  10. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).

    Article  CAS  Google Scholar 

  11. International Diabetes Federation <http://www.idf.org/>.

  12. American Diabetes Association <http://www.diabetes.org/>.

  13. IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davidson, M., Bate, G. & Kirkpatrick, P. Exenatide. Nat Rev Drug Discov 4, 713–714 (2005). https://doi.org/10.1038/nrd1828

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1828

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing